Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04335721 · ClinicalTrials.gov registry record · Phase 1
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04335721 is a Phase 1 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 12 participants.
The verdict
NCT04335721, a Phase 1 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemoglobinuria and urine albumin concentration ≥ 30 mg/g creatinin
Interventions
- DRUG Voxelotor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04335721
The ClinicalTrials.gov registry entry for NCT04335721 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voxelotor is the first listed.
NCT04335721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04335721 about?
NCT04335721 is a clinical study titled "A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease". This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemogl...
What is the current status of trial NCT04335721?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-03-16. Estimated completion is 2024-10-07.
What interventions are being tested in trial NCT04335721?
The interventions under investigation include: Voxelotor (DRUG).
Who is sponsoring clinical trial NCT04335721?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.